KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Net Income towards Common Stockholders: 2009-2024

Historic Net Income towards Common Stockholders for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Dec 2024 value amounting to -$535.6 million.

  • Vertex Pharmaceuticals' Net Income towards Common Stockholders rose 3.59% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year increase of 865.96%. This contributed to the annual value of -$535.6 million for FY2024, which is 114.80% down from last year.
  • According to the latest figures from FY2024, Vertex Pharmaceuticals' Net Income towards Common Stockholders is -$535.6 million, which was down 114.80% from $3.6 billion recorded in FY2023.
  • In the past 5 years, Vertex Pharmaceuticals' Net Income towards Common Stockholders ranged from a high of $3.6 billion in FY2023 and a low of -$535.6 million during FY2024.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was $3.3 billion (2022), whereas its average is $2.1 billion.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Net Income towards Common Stockholders spiked by 130.43% in 2020 and then crashed by 114.80% in 2024.
  • Over the past 5 years, Vertex Pharmaceuticals' Net Income towards Common Stockholders (Yearly) stood at $2.7 billion in 2020, then declined by 13.63% to $2.3 billion in 2021, then spiked by 41.84% to $3.3 billion in 2022, then grew by 8.96% to $3.6 billion in 2023, then tumbled by 114.80% to -$535.6 million in 2024.